Clinical Trial Update: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) [Phase 2]

View source ↗

Summary

A Phase 2 study of CS1001 in relapsed or refractory Extranodal Natural Killer/T-Cell Lymphoma has completed enrollment with results posted on 2024-06-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma

Drugs mentioned

• CS1001

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Extranodal Natural Killer/T-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-18